Tear functions in patients with vitiligo

Güngör, Şükrü; Nurözler, Ayşe Burcu; Akbay, Gülfer; Ekşioğlu, Meral

doi:10.1111/ijd.12779

Cited by 9 publications

(21 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, it could reasonably be argued that the treatment of vitiligo should be fully covered as is the case with eczema and psoriasis treatments. In addition to the visual impact of vitiligo, patients may report experiencing uncomfortable symptoms such as sunburn and itch, 20 among other systemic associations 28 including cochlear 27,31 and tear dysfunction 32 . Given its nature as a disease, significant impact on quality of life, and potential associated complications, vitiligo is not purely cosmetic in nature.…”

Section: Discussionmentioning

confidence: 99%

The scope of health insurance coverage of vitiligo treatments in the United States: Implications for health care outcomes and disparities in children of color

Blundell

Sachar

Gabel

et al. 2021

Pediatric Dermatology

View full text Add to dashboard Cite

Background Patients of color are disproportionately impacted by vitiligo. Access to treatment depends greatly on insurance coverage. We, therefore, assessed current vitiligo treatment coverage policies across major United States health insurers to determine current patterns and coverage gaps for vitiligo. Methods The study surveyed 15 commercial health care insurers, 50 BlueCross BlueShield (BCBS) plans, Medicare, Medicaid, and Veterans Affairs. Information on treatment coverage for vitiligo, specifically pimecrolimus and tacrolimus, excimer laser therapy, PUVA, and narrow‐band (nb)UVB, was collected via an online review of insurance policy documents, confirmed with phone calls to organization representatives, or via a survey of Medicaid providers, and state Medicaid directors. Results Of 17 organizations with regional or national coverage policies, 12% did not cover topical calcineurin inhibitors, 56% did not cover nbUVB phototherapy, 53% did not cover PUVA phototherapy, and 41% did not cover laser therapy. For BCBS, pimecrolimus and tacrolimus were not covered in 39% and 35% of states, respectively. NbUVB and PUVA therapy were not covered in 20% and 10% of states, respectively. Excimer laser therapy was not covered in 82% of states. Out of 32 states with accessible Medicaid information, 11 did not cover topicals, 5 did not cover nbUVB, 4 did not cover PUVA, and 7 did not cover laser. Two commonly cited reasons for coverage denial were that the treatment indication was considered cosmetic, and certain therapies are not FDA‐approved. Conclusions There is inequity in the distribution of health among vitiligo patients given current patterns of insurance coverage for treatment, which may have disproportionate impact on patients of color.

show abstract

Section: Discussionmentioning

confidence: 99%

The scope of health insurance coverage of vitiligo treatments in the United States: Implications for health care outcomes and disparities in children of color

Blundell

Sachar

Gabel

et al. 2021

Pediatric Dermatology

View full text Add to dashboard Cite

show abstract

“…Güngör et al 16 investigated TBUT and Schirmer test in 34 patients with different types of vitiligo. They found that the Schirmer test values in patients with vitiligo were insignificantly lower than those in the control subjects.…”

Section: Discussionmentioning

confidence: 99%

Dry Eye and Meibomian Glands in Vitiligo

Taheri¹,

Allahyari²,

Rudi³

et al. 2021

tjo

View full text Add to dashboard Cite

Objectives: To evaluate aqueous and lipid tear film parameters and the meibomian glands (MGs) with non-contact meibography in patients with vitiligo. Materials and Methods: This case-control study was conducted in the right (OD) and left (OS) eyes of 43 patients with vitiligo and 43 controls in Birjand, Iran. In addition to demographic information and skin disease characteristics, the Ocular Surface Disease Index (OSDI) questionnaire was completed for each patient, followed by eye examinations including slit lamp examination, Schirmer test, strip meniscometry (SMTube), and tear break-up time (TBUT) measurement. The MGs were also imaged using a non-contact meibography system (SBM System, Italy). The data were analyzed using SPSS version 22.0 with a significant level of less than 0.05. Results: Patients had higher OSDI score than controls but it was not significant (10.90±13.03 vs. 5.57±6.85; p=0.07). There were significant differences between the groups in mean Schirmer test values for both eyes (OD: 8.07±5.47 vs. 17.37±6.52; OS: 7.60±5.00 vs. 17.30±6.44, p<0.001) and mean SMTube results (OD: 4.49±2.40 vs. 9.74±3.67; OS: 4.30±2.81 vs. 9.65±4.52; p<0.001). However, mean TBUT did not differ between the groups (OD: 9.14±3.17 vs. 10.12±2.08, p=0.27; OS: 9.16±3.30 vs. 10.05±2.10, p=0.25). Meibography also showed no significant difference in MG dropout between the groups (OD: 20.86±9.79 vs. 21.05±12.07; p=0.74; OS: 18.16±8.83 vs. 19.53±10.30; p=0.51). Conclusion: Vitiligo is associated with a reduction in the production of aqueous tear film, but does not affect the structure and function of the MGs.

show abstract

“…Se encontró una adecuada función de la glándula lacrimal mediante la prueba de Schirmer, pero un tiempo más corto de ruptura de la película lacrimal, asociado a mayor presencia de un patrón inflamatorio y disminución de las células caliciformes (productoras de mucina de la película lacrimal), en la biopsia de la superficie ocular del grupo con vitiligo periocular comparado con el grupo control; los autores no descartaban que estos cambios fueran secundarios a enfermedades autoinmunitarias asociadas a vitiligo, no diagnosticadas (24). En otros dos estudios en los cuales evaluaron también la prueba de Schirrmer y el tiempo de ruptura de la película lacrimal, obtuvieron resultados similares, pero además, hallaron un mayor compromiso en estas pruebas en casos de vitiligo periocular y acrofacial (25,26).…”

Section: Enfermedades Oculares Asociadas a Vitiligounclassified

“…Esta actúa como moduladora de la transducción del estímulo auditivo en el oído interno además de participar en la protección del daño oxidativo celular ocular y vestibular, entre otros. Además, podrían 197 humanos >40 años/ sanos estar relacionadas vías inmunológicas afines, como la vía común de participación de Th17 en vitíligo, y en la disfunción lagrimal en el síndromede ojo seco (25,35,(50)(51)(52)(53). En conclusión, no hay suficientes estudios sobre la enfermedad ocular ni la auditiva en el vitíligo.…”

Section: Asociación De Enfermedad Auditivaunclassified

Enfermedad ocular y auditiva asociada al vitiligo

Casas¹,

Torres²

2017

rev. asoc. colomb. dermatol. cir. dematol.

View full text Add to dashboard Cite

El vitiligo es un trastorno de la pigmentación cuyo origen no es claro, secundario a la pérdida de la función de los melanocitos que podría comprometer no solo los melanocitos epidérmicos, sino también, aquellos dispuestos en otros órganos, lo cual sugiere la presencia de enfermedades concomitantes como alteraciones oculares y auditivas, las cuales se revisaran en este artículo. Se propone la necesidad de un examen visual y auditivo en el abordaje integral de los pacientes con vitiligo para descartar dicho compromiso.

show abstract

Tear functions in patients with vitiligo

Abstract: This study revealed that there is a decrease in tear production in patients with vitiligo, particularly in those with the acrofacial type of vitiligo.

Cited by 9 publications

References 19 publications

The scope of health insurance coverage of vitiligo treatments in the United States: Implications for health care outcomes and disparities in children of color

The scope of health insurance coverage of vitiligo treatments in the United States: Implications for health care outcomes and disparities in children of color

Dry Eye and Meibomian Glands in Vitiligo

Enfermedad ocular y auditiva asociada al vitiligo

Contact Info

Product

Resources

About